Get the Stockscreener App
1.46
10.61%
0.14
After Hours:
1.57
0.11
+7.53%
Inflarx N V stock is traded at $1.46, with a volume of 317.30K.
It is up +10.61% in the last 24 hours and up +8.96% over the past month.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
See More
Previous Close:
$1.32
Open:
$1.32
24h Volume:
317.30K
Relative Volume:
0.49
Market Cap:
$98.01M
Revenue:
-
Net Income/Loss:
$-46.12M
P/E Ratio:
-1.6894
EPS:
-0.8642
Net Cash Flow:
$-41.02M
1W Performance:
+4.29%
1M Performance:
+8.96%
6M Performance:
-14.12%
1Y Performance:
-5.81%
1-Day Range:
$1.32
$1.46
1-Week Range:
$1.30
$1.71
52-Week Range:
$0.7113
$2.815
Inflarx N V Stock (IFRX) Company Profile
Compare IFRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.46 | 89.43M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-02-25 | Resumed | H.C. Wainwright | Buy |
| May-29-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-23 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-28-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-28-21 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-11-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-06-20 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Oct-08-20 | Initiated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Apr-30-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-05-19 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-05-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-05-19 | Downgrade | JP Morgan | Overweight → Underweight |
| Jun-05-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-05-19 | Downgrade | SunTrust | Buy → Hold |
| Jan-29-19 | Initiated | Robert W. Baird | Outperform |
| Dec-10-18 | Initiated | Credit Suisse | Outperform |
| Jul-13-18 | Initiated | BMO Capital Markets | Outperform |
| Jun-28-18 | Initiated | Raymond James | Outperform |
| Jun-28-18 | Initiated | SunTrust | Buy |
| Feb-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
View All
Inflarx N V Stock (IFRX) Latest News
Can InflaRx N.V. recover in the next quarter2025 Trading Recap & Risk Controlled Swing Alerts - newser.com
Why InflaRx N.V. stock remains a top recommendationJuly 2025 Volume & Consistent Growth Equity Picks - newser.com
Reversal indicators forming on InflaRx N.V. stock2025 Sector Review & Daily Chart Pattern Signal Reports - newser.com
How geopolitical tensions affect InflaRx N.V. stockJuly 2025 Highlights & Low Risk Entry Point Tips - newser.com
How InflaRx N.V. stock performs after earningsGap Up & Safe Capital Allocation Plans - newser.com
Volatility clustering patterns for InflaRx N.V.Recession Risk & Technical Pattern Recognition Alerts - newser.com
InflaRx NV IF0 Stock Analysis and ForecastEarnings Growth Projections & Learn to Think Like a Long-Term Investor - earlytimes.in
InflaRx N.V. (NASDAQ:IFRX) Short Interest Update - MarketBeat
How reliable is InflaRx N.V. (IF0) stock dividend growthIPO Watch & Daily Profit Maximizing Tips - newser.com
Will InflaRx N.V. (IF0) stock deliver compounding returnsIPO Watch & Free Growth Oriented Trading Recommendations - newser.com
Institutional scanner results for InflaRx N.V.July 2025 PreEarnings & Stock Portfolio Risk Control - newser.com
Can InflaRx N.V. stock rebound after recent weaknessTrade Volume Summary & Daily Chart Pattern Signals - newser.com
Will InflaRx N.V. (IF0) stock outperform benchmarksJuly 2025 Short Interest & AI Powered Market Entry Ideas - newser.com
Will InflaRx N.V. (IF0) stock deliver stable dividends2025 Winners & Losers & High Win Rate Trade Tips - newser.com
What hedge fund moves indicate for InflaRx N.V. (IF0) stockJuly 2025 Review & Real-Time Chart Breakout Alerts - newser.com
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why InflaRx N.V. stock remains resilient2025 Investor Takeaways & Weekly Watchlist for Consistent Profits - fcp.pa.gov.br
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Bevacizumab - MSN
Can InflaRx N.V. stock maintain operating marginsQuarterly Trade Report & Short-Term High Return Ideas - Fundação Cultural do Pará
What makes InflaRx N.V. stock attractive to growth funds2025 Top Gainers & Reliable Price Breakout Alerts - newser.com
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab - TipRanks
What catalysts could drive InflaRx N.V. stock higherQuarterly Earnings Report & High Conviction Trade Alerts - Fundação Cultural do Pará
Inflarx N V Stock (IFRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):